J&J, in rebuttal to pricing criticism, says antidepressant Spravato is cost-effective - FiercePharma

Submitted by Anonymous (not verified) on Wed, 05/22/2019 - 13:01

J&J, in rebuttal to pricing criticism, says antidepressant Spravato is cost-effective  FiercePharmaDays ago, Johnson & Johnson's controversial nasal depression drug Spravato was criticized as being too pricey. In response, the company has now come up ...